重组人粒细胞集落刺激因子对化疗后中性粒细胞缺乏的有效性和安全性研究

Analysis of Efficacy and Safety of Recombinant Human Granulocyte Colony-stimulating Factor Used for Agranulocytosis Patients after Chemotherapy

目的：评价重组人粒细胞集落刺激因子（rhG-CSF）对化疗所致中性粒细胞缺乏的恶性血液病患者的临床疗效和安全性。方法：对2012年1~12月我院73例化疗后出现中性粒细胞缺乏的恶性血液病患者进行调查分析，均在粒缺发生后使用rhG-CSF，用SPSS统计软件对信息进行分析。结果：rhG-CSF可以有效缓解化疗后的中性粒细胞缺乏，使白细胞和中性粒细胞数目明显升高，平均恢复时间为（7.77±5.14） d，总有效率为95.9%，研究中根据病人中性粒细胞缺乏发生程度、阶段及持续时间进行个体化给药。结论：rhG-CSF对化疗所致的中性粒细胞缺乏症安全有效。

Objective： To evaluate the efficacy and safety of recombinant human granulocyte colony-stimulating factor （rhG-CSF） used for chemotherapy induced agranulocytosis in patients with hematological malignancies. Methods： Seventy-three patients with hematological malignancies suffering from agranulocyto_sis after chemotherapy were given rhG-CSF in our hospital during 2012. Data were statistically analyzed. Results： It was effective for chemotherapy induced agranulocytosis with rhG-CSF and the number of neu_trophile granulocytes and white blood cells （NEU and WBC） increased significantly. The average duration of recovery was 7.77±5.14 d and the effective rate was 95.9%. Individualized administration was based on the severity, phase and duration of agranulocytosis. Conclusion： rhG-CSF can be effective and safe to treat a_granulocytosis after chemotherapy.